[Action of monoclonal antibody against a hepatocellular carcinoma cell line (PLC/PRF/5)].
Monoclonal antibody (A9-84) against a hepatocellular carcinoma cell line (PLC/PRF-5) was produced by somatic cell fusion. The hybridoma clones were screened by a rapid solid-phase enzyme-linked binding assay. The target cells were cultured in 96-well Linbro plate and fixed by methanol for screening. The specificity of the antibody was studied by enzyme-linked binding assay and immunofluorescence methods. It shows that A9-84 do not respond to 8 different human cancer cell lines (4 liver cancer, 1 esophageal cancer, 1 stomach cancer, 1 multiple myeloma and 1 lymphoblast cell line) and the peripheral mononuclear cells of 91 normal subjects. A9-84 is the subtype of IgG3. It is capable of inhibiting the growth of cultured PLC/PRF/5 cells with or without complement.
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000912:Antibodies, Neoplasm / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000473:pathology; D002460:Cell Line; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm